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With rising rates of drug-resistant infections, there is a need for
diagnostic methods that rapidly can detect the presence of
pathogens and reveal their susceptibility to antibiotics. Here we
propose an approach to diagnosing the presence and drug-suscep-
tibility of infectious diseases based on direct detection of RNA
from clinical samples. We demonstrate that species-speciﬁc RNA
signatures can be used to identify a broad spectrum of infectious
agents, including bacteria, viruses, yeast, and parasites. Moreover,
we show that the behavior of a small set of bacterial transcripts
after a brief antibiotic pulse can rapidly differentiate drug-suscep-
tible and -resistant organisms and that these measurements can be
made directly from clinical materials. Thus, transcriptional signa-
tures could form the basis of a uniform diagnostic platform appli-
cable across a broad range of infectious agents.
antibiotic resistance | genomics | tuberculosis
Successful treatment of infectious diseases requires not onlythe rapid identiﬁcation of the infecting organism but also
prompt determination of which antibiotics will be effective in
treating the infection. Delays in detecting drug-resistant infec-
tions in turn delay the implementation of effective therapy and
are associated with increased mortality (1, 2). Currently, hospi-
tals still rely largely on an assortment of cultures, immunoassays,
and molecular techniques (3, 4) for diagnosis of infectious dis-
ease; these assays can be slow and require specialized training. A
prime example of the shortcomings of current diagnostics is tu-
berculosis: culture-based methods require a minimum of several
days to detect the presence of Mycobacterium tuberculosis, and
drug susceptibilities may not be known for weeks to months after
the initial visit to the clinic (5).
One approach to increase the speed, precision, and generality
of infectious-disease diagnostics is to use DNA-based techni-
ques, which largely involve enzymatic ampliﬁcation of speciﬁc
DNA sequences (4, 6–8). To date, such approaches have been
deployed only in limited settings, as in identifying speciﬁc viral
pathogens or fastidious organisms that are challenging to culture,
such as the causative agents of gonorrhea and Chlamydia (6, 9).
Identiﬁcation of pathogens using DNA-based approaches re-
quires knowledge only of the pathogen genome sequence; how-
ever, DNA-based detection of antibiotic resistance presents a
much greater challenge, requiring precise knowledge of the ge-
nomic features that confer resistance, thus limiting the method
to known resistance genotypes. Examples of these features in-
clude resistance-conferring genetic elements [e.g., the mecA
gene in methicillin-resistant Staphylococcus aureus (MRSA) (10,
11)] or known resistance-associated polymorphisms [e.g., muta-
tions in rpoB in rifampin-resistant M. tuberculosis (12, 13)].
However, a fundamental limitation is that the known genetic
elements or mutations typically constitute only a fraction of the
genetic basis for clinically relevant resistance.
Here we explore an alternative approach: using RNA de-
tection to obtain both genotypic and phenotypic information.
Like DNA, RNA contains abundant genomic information to al-
low accurate identiﬁcation of pathogens. However, unlike DNA,
the RNA transcriptome also provides critical dynamic phenotypic
information. Brief antibiotic exposure can trigger transcriptional
responses in susceptible, but not in resistant, microbes within a
few minutes (14), providing a means to couple pathogen identi-
ﬁcation directly with antibiotic-susceptibility testing.
In this work, we provide a proof-of-principle for RNA-based
detection and drug-resistance testing of pathogens. Speciﬁcally,
we demonstrate that detection of a set of pathogen RNA tran-
scripts can provide ample speciﬁcity to diagnose precisely the
presence of a broad range of pathogens and, more critically, to
distinguish antibiotic-susceptible and -resistant organisms. The
natural abundance of RNA transcripts, along with improved
RNA detection methods, allows us to measure these expression
signatures directly from patient samples without the need for
organism isolation or nucleic acid puriﬁcation and ampliﬁcation.
In our experiments, we used a simple commercially available
method for RNA quantitation (nCounter analysis, NanoString
Technologies) that involves minimal sample processing and no
enzymatic manipulation (15). RNA in crude culture lysates or
patient specimens is hybridized with a pool of ﬂuorescently bar-
coded oligonucleotide probes designed to target speciﬁc tran-
scripts from a broad collection of organisms of interest. For
a given organism, the designed probes target transcripts that
identify the organism uniquely at the species level and simulta-
neously allow its transcriptional response to antibiotic exposure
to be measured. Because large numbers of transcripts are in-
vestigated in a pool, organism identity and drug sensitivity are
determined in a single assay. Although this assay is well suited for
these proof-of-principle studies, continued innovation in this and
other quantitative nanosensor technologies likely will lead to
tools for even more rapid RNA detection.
Results
RNA-Based Pathogen Detection. We ﬁrst sought to identify path-
ogens through direct detection of RNAs speciﬁc to the species.
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As an initial test, we targeted three Gram-negative pathogens:
Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneu-
moniae. To identify organism-speciﬁc sequences for probe de-
sign, we analyzed publicly available coding sequences from
multiple isolates of each of these three pathogens to ﬁnd genes
that are highly conserved within but not between species. We
generated a pool of probes targeting these species-speciﬁc
mRNAs, including four or ﬁve probes for each organism to ob-
tain desired levels of speciﬁcity. (Probe lists are given in SI Ap-
pendix, Table S1.) We were able to detect and distinguish each
organism in pure culture (Fig. 1A) and in a complex mixture
including eight additional Gram-negative pathogens by directly
probing crude lysates (SI Appendix, Fig. S1). Because microbio-
logic diagnosis of M. tuberculosis is among the slowest diagnosis
made in a clinical setting, we then sought to extend our ﬁndings
to this pathogen. We designed probes to both genes conserved
throughout the genus Mycobacterium and genes speciﬁc to M.
tuberculosis and were able to distinguish M. tuberculosis from
other pathogenic mycobacteria (Fig. 1B).
To transform these data into a binary determination of the
presence or absence of a pathogen in a given sample, we con-
densed the counts from multiple transcripts into a single metric
that assesses the presence or absence of an organism, using the
mean of the natural logarithm of the raw counts from each probe,
normalized for hybridization efﬁciency using internal controls.
When applied to a set of 17 clinical E. coli isolates, every isolate
was differentiated easily from a set of 13 non-E. coli samples (Z
score > 6.5 relative to non-E. coli controls; Fig. 1C). This method
also was effective when applied across a wider range of bacterial
pathogens, including K. pneumoniae, P. aeruginosa, M. tubercu-
losis, Proteus mirabilis, Staphylococcus aureus, Streptococcus
pneumoniae, Streptococcus pyogenes, and Stenotrophomonas
maltophilia (SI Appendix, Fig. S2 and Table S2). Of note, the
speciﬁcity of the probes allowed us to distinguish between spe-
cies within a genus easily (the two streptococcal species were not
detected with the other’s probes, and Klebsiella oxytoca strains
were not detected with K. pneumoniae probes).
Because RNA is universal in pathogens ranging from bacteria,
viruses, and fungi to parasites, RNA detection can provide
a common diagnostic platform applicable across a broad range of
infectious agents. Using a large pool of mixed pathogen probes,
we were able directly and speciﬁcally to detect signals to identify
inﬂuenza virus, herpes simplex virus-2 (HSV-2), and HIV-1 in
cell culture in a dose-dependent manner (Fig. 2 A–C); the fungal
pathogen Candida albicans (Fig. 2D); and the different stages of
the Plasmodium falciparum life cycle in infected erythrocytes
(Fig. 2E). As with bacterial detection, viral detection was highly
speciﬁc; HSV-2 probes did not detect HSV-1 virus even at rel-
atively high multiplicity of infection (MOI) (Fig. 2B). Current
clinical laboratory practice uses a range of techniques from
standard culture to ﬂuorescent microscopy to diagnose infections
with these organisms; however, RNA-based direct detection has
the potential to streamline identiﬁcation of almost all potential
infectious agents into a single platform.
RNA-Based Determination of Drug Susceptibility. In the clinical
setting, determining appropriate therapy requires knowing not
only which pathogens are present but also their antibiotic sus-
ceptibilities. We thus sought to demonstrate that RNA detection
can be used to determine antibiotic resistance rapidly. In the case
of mobile genetic elements that encode drug-resistance genes,
detection of transcripts from known elements would enable us to
determine resistance genotypically, in a manner analogous to
PCR-based approaches that detect resistance-encoding genes in
some bacteria (16–18). To demonstrate that an RNA-based ap-
proach is able to detect such resistance genes, we probed S. aureus
isolates for mecA mRNA, which confers resistance to methicillin,
and Enterococcus isolates for vanA mRNA, which confers re-
sistance to vancomycin. In both cases, we could detect the relevant
transcript (Fig. 3A), thus allowing rapid identiﬁcation of MRSA
and vancomycin-resistant Enterococcus (VRE), with the potential
to match PCR-based methods while bypassing the need for
nucleic acid isolation, puriﬁcation, and ampliﬁcation. In principle,
this method can be extended to other genetic determinants of
pathogenicity, such as virulence factors acquired through hori-
zontal genetic exchange in food-borne pathogens [e.g., Shiga toxin
in enterohemorrhagic or Shiga toxigenic E. coli (19)].
We then sought to extend RNA-based determination of anti-
biotic resistance beyond the detection of speciﬁc known geno-
types. Antibiotic exposure can trigger a stereotypical transcrip-
tional response in susceptible microbes as rapidly as within a few
minutes (14). For example, when treated with ciproﬂoxacin,
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Fig. 1. Identiﬁcation of bacteria in culture with direct RNA detection. (A and B) Bacterial cultures were lysed and analyzed with nCounter probes for species-
speciﬁc transcripts. y axis: transcript raw counts; x axis: gene. Each bar represents the average and SD of two biological replicates. (A) Detection from culture
of Gram-negative bacteria. Probes are shown for E. coli (black bars), K. pneumoniae (white bars), and P. aeruginosa (gray bars). (B) Genus- and species-speciﬁc
detection of mycobacteria in culture:M. tuberculosis (Mtb),M. avium subsp. intracellulare (MAI),M. paratuberculosis (Mpara), andM.marinum (Mmar). Gray
bars show genus-wide probes; black bars showM. tuberculosis-speciﬁc probes. (C) Synthesis of four E. coli probes into a single organism ID score. The natural
logs of the observed counts for each transcript were averaged. Each point represents a single strain. The dashed line indicates three SDs from the mean of the
non-E. coli samples (P = 0.0027).
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P. aeruginosa up-regulates both recA and lexA, part of the ca-
nonical SOS response (20). These transcriptional programs
represent one of the earliest detectable cellular changes that
distinguish susceptible and resistant organisms. For many or-
ganism/antibiotic pairings, these responses have been well char-
acterized using microarrays. We hypothesized that sensitive
organisms exposed to drug would display a stereotypical tran-
scriptional signature, but resistant organisms, regardless of the
mechanism of resistance, would show no response, thus pro-
viding a basis for rapidly distinguishing antibiotic-susceptible
from antibiotic -resistant strains based on phenotype.
Using published data from Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/) or ArrayExpress (http://www.ebi.ac.
uk/arrayexpress/), we identiﬁed genes that are regulated differ-
entially upon exposure to various antimicrobial agents and thus
can be used to indicate the presence or absence of a response.
We generated a pooled antibiotic-sensitivity probe set to detect
uniquely these genes for several pathogens of interest (14, 20,
21). Following a 10-min exposure of E. coli K-12 to ciproﬂoxacin,
we observed changes in transcript levels of a subset of genes that
together deﬁne a ciproﬂoxacin-susceptibility expression signa-
ture (Fig. 3B; probes are listed in SI Appendix, Table S7). A
similar signature was detected in an additional laboratory isolate
and in ﬁve clinical isolates tested (SI Appendix, Table S3). In
contrast, this signature was not elicited in the seven resistant
clinical strains tested (Fig. 3B and SI Appendix, Table S3). Sim-
ilarly, on exposure of antibiotic-susceptible E. coli strains to
gentamicin or ampicillin or on exposure of antibiotic-susceptible
P. aeruginosa strains to ciproﬂoxacin, we observed stereotypic
transcriptional responses speciﬁc to each antibiotic/microbe
combination (Fig. 3 B and C and SI Appendix, Table S3) that
were not elicited in resistant strains.
Some genes (e.g., recA, involved in the SOS response) are up-
regulated in several species in response to multiple antibiotics,
whereas other transcriptional changes are organism and/or
mechanism speciﬁc. For example, exposure of E. coli to the
β-lactam ampicillin [which blocks cell-wall synthesis and also
hinders proline transport (22)] induces opgG, involved in the
osmoregulated synthesis of periplasmic glucan (23), and proC,
which encodes a proline synthetic enzyme. In contrast, the
transcript levels of the majority of genes remain unchanged in
response to antibiotic exposure, underscoring the sufﬁciency of
following only a small subset of genes, i.e., a signature, rather
than the entire genome. It should be noted that genes selected in
this work were chosen based on a limited set of previously
published data, and additional genomewide monitoring of a
broader range of drug-susceptible isolates might improve these
signatures and thus strengthen this approach.
Rapid phenotypic testing for antibiotic susceptibility would
have a particularly profound impact in tuberculosis, because
established methods for phenotypic testing take weeks to months.
During this time, patients with unsuspected resistance who are
treated with standard therapy remain inappropriately treated,
potentially resulting in the development of further drug resistance
and worse outcomes. Moreover, until these patients receive ad-
equate therapy, they remain infectious and can spread drug-re-
sistant disease (24). We therefore deﬁned expression signatures
in response to the anti-tubercular agents isoniazid, ciproﬂoxacin,
and streptomycin (25) and showed that susceptible and resistant
laboratory and clinical isolates could be distinguished after 3–6 h
ga
g
re
v
no
n-
H
IV
U HIV-1
ga
g
re
v
no
n-
H
IV
101
102
103
104
105
1
ring/troph troph/early schizont schizont early ring
0.1% parasitemiauninfected 10% parasitemia
I1
02
0c
C
08
00
w
A
01
10
w
07
_0
12
8
13
_0
23
3
E
06
60
c
06
60
w
D
11
70
c
no
n-
P
f
I1
02
0c
C
08
00
w
A
01
10
w
07
_0
12
8
13
_0
23
3
E
06
60
c
06
60
w
D
11
70
c
no
n-
P
f
I1
02
0c
C
08
00
w
A
01
10
w
07
_0
12
8
13
_0
23
3
E
06
60
c
06
60
w
D
11
70
c
no
n-
P
f
co
un
ts
01
03
01
46
01
97
03
99
no
n-
C
a
101
102
103
104
M
at
rix
 
no
n-
flu
M
at
rix
 
no
n-
flu
M
at
rix
 
no
n-
flu
101
102
103
104
105
106 MOI0.01
MOI 1U
co
un
ts
gp
G
no
n-
H
S
V
2
gp
G
no
n-
H
S
V
2
gp
G
no
n-
H
S
V
2
gp
G
no
n-
H
S
V
2
MOI
0.01
MOI
1
HSV-1
MOI=1
U
A B C D
E
Fig. 2. RNA-based identiﬁcation of viruses, a fungus, and a parasite by di-
rect analysis of lysates using nCounter probes. Shaded bars indicate organ-
ism-speciﬁc probes, white bars indicate average of non-organism probes. (A)
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Fig. 3. RNA signature-based determination of antimicrobial susceptibility.
(A) Detection of resistance genes on mobile genetic elements. For MSSA and
MRSA: detection of mecA transcript upon cloxacillin exposure. For vanco-
mycin-sensitive Enterococcus (VSE) and VRE: detection of vanA upon van-
comycin exposure. Each point represents a different clinical isolate. (B–D)
Transcriptional responses to drug exposure. Log-phase cultures were ex-
posed to antibiotic, lysed, and analyzed using nCounter probe sets. Counts
were normalized to the mean of the middle 50% of all counts for a sample,
and induction was determined by comparing drug-exposed and unexposed
samples. Genes contributing to the signature are on the x axis. Shown are
the responses of a panel of susceptible (black bars, Upper) or resistant (gray
bars; Lower) strains of E. coli to ciproﬂoxacin (CIP), ampicillin (AMP), or
gentamicin (GM) (B); of P. aeruginosa to ciproﬂoxacin (C); and of M. tu-
berculosis to isoniazid (INH), streptomycin (SM), or ciproﬂoxacin (D). Error
bars represent SD of three to seven isolates tested. See SI Appendix, Table S3
for a full list of strains tested. (E) SPD of E. coli laboratory and clinical isolates
exposed to ciproﬂoxacin. Transcriptional responses of each tested isolate
were condensed into a single metric, SPD. The dashed line indicates three
SDs from the mean of the resistant samples. Each point represents one strain
performed in two to four biological replicates.
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of exposure to the antibiotic (Fig. 3D). Some genes in the tran-
scriptional proﬁles are mechanism speciﬁc (e.g., alkA and lhr for
ciproﬂoxacin; groEL for streptomycin; and kasA and accD6 for
isoniazid) (25, 26). Other genes, particularly those involved in
mycolic acid synthesis or intermediary metabolism, are down-
regulated in response to multiple antibiotics, indicating a shift
away from growth toward damage control.
As with organism identiﬁcation, we transformed the tran-
scriptional signatures elicited by drug exposure into a binary
outcome indicative of sensitivity or resistance. To condense the
transcriptional responses into a single, quantitative metric, we
calculated the squared projected distance (SPD) of the expres-
sion response from each experimental sample along a vector
from the centroid of control, antibiotic-susceptible samples to
the centroid of resistant controls (a detailed description of this
metric is provided in the SI Appendix). Strains susceptible to
a given antibiotic show closely clustered transcriptional respon-
ses, resulting in small SPDs (SI Appendix, Table S3). Conversely,
antibiotic-resistant strains have larger SPD values, the result of
the signature genes failing to respond to antibiotic. Using this
metric, we can clearly separate sensitive and resistant laboratory
and clinical isolates of E. coli (Fig. 3E and SI Appendix, Fig. S3),
P. aeruginosa (SI Appendix, Fig. S4), and M. tuberculosis (Fig. 4B
and SI Appendix, Fig. S5).
Because transcription represents a phenotypic response to an-
tibiotic exposure, we hypothesized that the sensitive signature
should not be elicited in resistant strains regardless of the mech-
anism of resistance. To evaluate this principle, we engineered a set
of isogenic strains with distinct, well-characterized resistance
mechanisms and compared their transcriptional responses to an-
tibiotic exposure.We tested ﬁve ciproﬂoxacin-resistant mutants of
E. coli strain J53, each engineered to carry a different mechanism
of resistance: two with single mutations in the ﬂuoroquinolone
target gene topoisomerase gyrA (G81D or S83L) and three car-
rying plasmid-mediated quinolone-resistance genes with distinct
mechanisms of action (27) including aac(6′)-Ib, which encodes an
acetylating, inactivating enzyme; qnrB, which encodes a protein
that blocks the active site of GyrA; and oqxAB, which encodes an
efﬂux pump (Fig. 4A). The susceptible parent strain, J53, dem-
onstrated the expected signature upon ciproﬂoxacin exposure and
a small SPD similar to that of other drug-sensitive isolates (SI
Appendix, Table S3). However, none of the ciproﬂoxacin-resistant
mutants showed the sensitivity signature upon ciproﬂoxacin ex-
posure, and all had large SPDs, thus conﬁrming that an expression
signature can distinguish resistant from sensitive strains, in-
dependent of the mechanism of resistance.
To demonstrate the applicability of this principle beyond E.
coli, we tested M. tuberculosis isolates with known distinct
mechanisms of resistance to the ﬁrst-line drug isoniazid. The ﬁrst
resistant strain has a mutation in katG, which encodes a catalase
necessary for prodrug activation (28); the second has a mutation
in the promoter of inhA, which encodes the target of isoniazid
(29). Because of these distinct mechanisms, these two strains
have differing levels of resistance to isoniazid: The katG mutant
shows high-level resistance [minimum inhibitory concentration
(MIC) >6.4 μg/mL], whereas the inhA promoter mutant has
lower-level resistance (MIC = 0.4 μg/mL). Exposure of the
sensitive laboratory strain H37Rv to either low (0.2 μg/mL) or
high (1 μg/mL) concentrations of isoniazid elicited the expected
transcriptional signature. Exposure to the lower isoniazid con-
centration failed to elicit a transcriptional response in either
resistant strain, but at the higher isoniazid concentration, the
inhA mutant responded in a susceptible manner, in contrast to
the katG mutant (Fig. 4C). This result conﬁrms that the loss of
the transcriptional signature is independent of mechanism.
Moreover, it suggests that the concentrations required to elicit
responses can be used to differentiate high- and low-level
resistance.
Application of an RNA-Based Diagnostic to Simulated and Real Pa-
tient Specimens. To show that an RNA-based diagnostic platform
can be used to probe clinical specimens directly, we ﬁrst sought
to identify pathogens and their drug susceptibilities in blood
samples spiked with bacteria. We introduced MRSA or methi-
cillin-sensitive S. aureus (MSSA) or ciproﬂoxacin-sensitive
(CIPS) or -resistant (CIPR) E. coli into human blood samples and
then probed for pathogen RNA. From these samples, we were
able to identify the spiked organism directly (Fig. 5A) and si-
multaneously to detect both genotypic and phenotypic antibiotic
resistance. Using probes to mecA transcript, we were able to
distinguish MRSA from MSSA easily (Fig. 5A), and, using our
deﬁned expression signatures of antibiotic exposure, we were
able to distinguish CIPS from CIPR E. coli (Fig. 5B). We were
similarly successful using urine into which we had introduced E.
coli. We grew CIPS and CIPR isolates of E. coli in clean-caught
urine from healthy donors and probed directly for and detected
species-speciﬁc transcripts (Fig. 5A) as well as drug-sensitive
transcriptional responses upon CIP exposure (Fig. 5B).
Finally, we applied this method directly to clinical specimens
by testing 34 urine specimens collected from patients suspected
of having urinary tract infections based on a positive urine
analysis. A small aliquot of urine was pulsed with ciproﬂoxacin
for 30 min, lysed, and assayed in parallel with an unexposed al-
iquot, using a single probe set that included both identiﬁcation
and drug-susceptibility probes. For comparison, standard cul-
ture-based diagnostic tools were used for organism identiﬁcation
and drug-susceptibility testing [growth on selective/differential
media, testing of isolates using API 20E strips (bioMerieux,
Inc.), and microtiter plate-based MIC determinations; see SI
Appendix, Tables S8 and S9]. We were able to identify K. pneu-
moniae and P. aeruginosa in all specimens infected with these
organisms at levels greater than the standard clinical cutoff
(>105 organisms per milliliter of urine); these scores for these
culture-positive specimens differed from the scores of the cul-
ture-negative specimens by >12 SDs (Fig. 5C). Results for E. coli
were less clear because background counts for the E. coli probes
generally were higher than for the P. aeruginosa and K. pneu-
moniae probes. This background also was observed with non-
clinical materials and blank controls across multiple probe lots,
suggesting that the background signal is inherent to the Nano-
String assay and could represent low levels of nucleic acid con-
tamination in reagents. Nevertheless, all 17 E. coli-positive
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Fig. 4. Determination of antibiotic susceptibility is independent of the
mechanism of resistance. (A) Ciproﬂoxacin-sensitive E. coli J53 and deriva-
tives containing either a chromosomal mutation in gyrA or plasmid-medi-
ated quinolone resistance determinants [aac(6′)-Ib, qnrB, or oqxAB] were
exposed to ciproﬂoxacin. Error bars indicate mean and SD of two biological
duplicates from one of two independent experiments. (B) M. tuberculosis
laboratory and clinical isolates exposed to 1 μg/mL isoniazid. INH-R, iso-
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specimens scored higher than the 17 E. coli-negative specimens,
with 13 of the E. coli-positive specimens scoring more than three
SDs higher than the mean of the negative specimens. Finally,
using the data from the spiked urine samples (Fig. 5B) as
a training data set to deﬁne the ciproﬂoxacin sensitivity signature
in urine, we evaluated the 13 unknown E. coli-infected urine
specimens for ciproﬂoxacin sensitivity (Fig. 5D and SI Appendix,
Table S9). Samples were scored as sensitive if the SPD score fell
more than three SDs from the mean SPD of the resistant sam-
ples used in the training set. Using this cutoff, all 13 samples
were characterized correctly (100% accuracy, P = 0.00037).
Discussion
The current wealth of genomic and transcriptomic data available
should promote the development of substantially improved
diagnostics for infectious diseases. Our work suggests that an
RNA-based diagnostic can capitalize on this information by
taking advantage of both static genome sequences and dynamic
transcriptomic responses. Although additional testing will be
required to determine the full applicability of the approach, di-
rect RNA detection has the potential to identify most classes of
pathogens and to allow simultaneous phenotypic determination
of antibiotic susceptibility within a single assay. An RNA-cen-
tered diagnostic has two important advantages. First, the natural
abundance of single-stranded mRNA allows its direct detection
via hybridization, without puriﬁcation or ampliﬁcation. First, the
natural abundance of single-stranded mRNA allows its direct
detection via hybridization, without puriﬁcation, thus eliminating
the challenges of enzymatic ampliﬁcation. More critically, anti-
biotic-elicited RNA signatures are a rapid indicator of antibiotic
susceptibility; because these signatures are among the ﬁrst cel-
lular changes that occur upon drug exposure, they should allow
detection of resistance long before the traditional phenotype of
growth inhibition can be observed. Moreover, we have demon-
strated that transcriptional proﬁles reﬂect physiologic pheno-
types regardless of the underlying genotypic basis for resistance.
RNA detection thus has the potential to accelerate, unify, and
simplify diagnosis, particularly with regards to determining an-
tibiotic susceptibilities. Recently, RNA signatures have been
recognized as an important tool in guiding clinical practice in
cancer (30). Our work extends this application by measuring
dynamic changes in RNA signatures upon antibiotic exposure
rather than static baseline transcriptional proﬁles.
Although this paper provides a proof of principle, consider-
able additional work will be required to yield a clinic-ready,
RNA-based diagnostic for infectious diseases. First, probe-set
design will beneﬁt from the availability of more sequenced
genomes and additional transcriptomic data. Second, it will be
necessary to develop a fully automated, integrated system for
sample processing and detection, which will drive the speed,
sensitivity, and detection limit of the system [the current assay
detects 40–90 bacteria grown in culture; see SI Appendix, Fig.
S6]. Engineering also can facilitate the development of systems
suited to resource-poor settings. Third, it will be necessary to
benchmark the RNA signatures with conventional assays for
organism identiﬁcation and drug-susceptibility determination
and to run trials to determine statistically meaningful sensitivities
and speciﬁcities for the method. As an important step, the work
described here demonstrates the feasibility of this approach and
raises the possibility that an RNA-based diagnostic could meet
the critical need for more rapid diagnosis of infectious disease.
Materials and Methods
For expanded details of methods, see SI Appendix.
Selection of Organism-Identiﬁcation Probes. To select nCounter probes for
differential detection of Gram-negative organisms, we compared all publi-
cally available sequenced genomes for relevant organisms (SI Appendix,
Table S10). We identiﬁed genes conserved within each species by selecting
coding sequences (CDS) having at least 50% identity over at least 70% of the
CDS length for all sequenced genomes for pathogenic strains of that species
available at the time the probe sets were generated. We broke the CDS into
overlapping 50-mers and retained only those 50-mers with 100% identity
within a species and having no greater than 50% identity to a CDS in any
other species in the study. Available published expression data in Gene Ex-
pression Omnibus were reviewed, and genes with good expression under
most conditions were selected. Full details of this process are described in
SI Appendix.
Bacterial and Fungal Culture. All Gram-negative bacterial clinical isolates were
obtained from the Brigham and Women’s Hospital microbiology laboratory,
and clinical M. tuberculosis isolates were obtained from the Massachusetts
Supranational Tuberculosis Reference Laboratory. Bacterial or yeast cultures
were grown to an OD600 of ∼1 in LB medium. For mixing experiments, equal
numbers of bacteria as determined by OD600 were combined before lysis for
nCounter analysis. For spiked urine experiments, E. coli was grown overnight
at 37 °C in sterile urine, diluted 1:20, and grown to OD600 of 0.1–0.3 in fresh
urine before harvest or antibiotic exposure, as described below. Mycobac-
terium isolates were grown in Middlebrook 7H9 medium (BD Diagnostics)
supplemented with OADC (BD Diagnostics) and 0.2% glycerol.
Viral and Plasmodium Infections. HeLa cells (2 × 106), 293T cells (2 × 105), and
human peripheral blood monocytes (5 × 105) were infected with HSV-1
strain KOS and HSV-2 strain 186 Syn+, inﬂuenza A PR8, or HIV-1 NL-ADA,
respectively, at the noted MOIs. Primary red blood cells (5 × 109) were
infected with P. falciparum strain 3D7 until they reached the noted levels of
parasitemia. At the indicated times, the cells were washed once with PBS
and harvested as described below.
Antibiotic Exposure. Cultures of E. coli or P. aeruginosa were grown to an
OD600 of ∼1 in LB. Cultures then were divided into two samples, one of which
was treated with antibiotic (E. coli: ciproﬂoxacin 4–8 μg/mL or 300 ng/mL
or ampicillin 500 μg/mL for 10 min, gentamicin 64 μg/mL for 30 min;
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Fig. 5. Identiﬁcation of bacteria and determination of antibiotic suscepti-
bility directly from spiked samples and clinical urine specimens. (A) Detection
of species-speciﬁc transcripts in blood or urine spiked with S. aureus (SA) or
E. coli (EC) and discrimination of MSSA (MS) from MRSA (MR) by direct de-
tection ofmecA transcripts in spiked blood. The natural logs of the observed
counts for each of four species-speciﬁc transcripts were averaged to gener-
ate the organism ID score. +, spiked urine; −, healthy control urine. Each
point represents a different isolate. (B) Discrimination of ciproﬂoxacin-sen-
sitive (S) from ciproﬂoxacin-resistant (R) E. coli in spiked blood or urine using
expression signatures (expressed as SPD). (C) Detection of species-speciﬁc
transcripts in clinical urine specimens. + indicates the presence (>105/mL); –
indicates the absence (<105/mL) of the indicated species. Each point repre-
sents a different urine specimen. (D) Discrimination of CIPS from CIPR E. coli
in validated E. coli-positive (>105/mL) clinical urine specimens using expres-
sion signatures (expressed as SPD). Dashed lines in A and C indicate three SDs
from mean of control, nonorganism samples. Dashed lines in B and D in-
dicate three SDs from the mean of resistant samples.
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P. aeruginosa: ciproﬂoxacin 16 μg/mL for 30 min). Cultures of S. aureus or
Enterococcus were grown to an OD600 of ∼1 in LB. Cultures then were ex-
posed to cloxacillin (25 μg/mL) or vancomycin (128 μg/mL), respectively, for 30
min. Cultures of M. tuberculosis were grown to midlog phase and then were
normalized to OD600 of 0.2. Two milliliters of each culture were treated with
no antibiotic or with one of the following (ﬁnal concentration): isoniazid 0.2–
1.0 μg/mL for 3 h; streptomycin 5 μg/mL for 6 h, or ciproﬂoxacin 5 μg/mL for
3 h. Clinical samples, including spiked blood, spiked urine, and discarded
patient urines, were exposed to 4 μg/mL ciproﬂoxacin for 30 min. All bacterial
cultures and clinical materials were maintained at 37 °C during drug exposure.
Sample Processing. Gram-negative cultures were lysed directly in RLT buffer
(Qiagen). In addition, Gram-positive cultures were disrupted mechanically
with bead beating. For spiked blood samples, 1 × 107 bacteria were added
per milliliter of blood. Samples then were added to PAXgene blood RNA
tubes (PreAnalytix GmbH) and were processed according to the manu-
facturer’s protocol through the ﬁrst centrifugation. Then supernatant was
aspirated, pellets were resuspended in RLT buffer, and lysates were used
directly in hybridizations. For spiked urine and clinical specimens, urine was
added directly to RLT buffer. Mycobacterial cultures were centrifuged and
then were resuspended in TRIzol (Gibco) with or without mechanical dis-
ruption by bead beating, and the initial aqueous phase was collected for
analysis. Viral and parasite RNA were prepared similarly using TRIzol and
chloroform. For all lysates, 3–5 μL were used directly in hybridizations
according to standard nCounter protocols. For organism identiﬁcation, raw
scores were normalized to internal hybridization controls. To determine
antibiotic susceptibility, raw counts were normalized to the mean of the
middle 50% of all probes for a sample, and fold induction for each gene was
determined by comparing antibiotic-treated with untreated samples.
Processing of Clinical Urine Specimens. Discarded, de-identiﬁed urine speci-
mens positive for nitrites and leukocytes were obtained from the Brigham
and Women’s Hospital clinical laboratory. The time between collection and
processing ranged from 3–48 h. Laboratory sample processing was minimal,
consisting of a 30-min exposure of a collected urine specimen to antibiotic
followed by rapid lysis in RLT buffer. nCounter transcript detection was
performed according to the manufacturer’s recommendation for analysis of
mammalian genomes (18-h hybridization followed by a 5-h analysis on an
automated instrument). Microbial identiﬁcation and antibiotic susceptibility
were determined independently using standard laboratory protocols. For
full details see SI Appendix.
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